Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. develops clinical-stage Alzheimer’s disease therapeutics that target toxic soluble amyloid beta oligomers. The company’s recurring updates center on sabirnetug (ACU193), a humanized monoclonal antibody program, the ALTITUDE-AD and INTERCEPT-AD clinical study framework, and research on biomarkers and antibody selectivity.
Company news also covers Enhanced Brain Delivery (EBD™) work using transferrin-receptor-targeting blood-brain barrier technology, subcutaneous formulation research using ENHANZE® drug delivery technology, collaborations, conference presentations, operating results, financing activity, and management participation in health care and CNS investor events.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported new preclinical and patient-experience data from its Enhanced Brain Delivery™ (EBD™) program and ALTITUDE-AD Phase 2 trial at AAIC® 2026 in London. In collaboration with JCR Pharmaceuticals, bispecific antibodies targeting both soluble amyloid beta oligomers (AβOs) and human transferrin receptor (hTfR) showed substantially improved brain penetration in mouse and non-human primate models.
EBD candidate ACU401 achieved up to 40-fold higher frontal cortex exposure versus ACU234 in cynomolgus monkeys, with similar increases in hippocampus and putamen and no hematological findings suggestive of anemia. Semi-structured interviews from 38 ALTITUDE-AD participants and partners highlighted pervasive memory challenges, emotional burden, social withdrawal, and coping strategies, underscoring the importance of directly capturing patient experience in early Alzheimer’s disease.
Acumen Pharmaceuticals (NASDAQ: ABOS) will present three studies at AAIC 2026 in London from July 12-15, 2026. One oral and two poster presentations will cover Enhanced Brain Delivery (EBD) bispecific antibodies using transferrin-receptor targeting and patient-perspective insights from the ALTITUDE-AD early symptomatic Alzheimer’s disease trial population.
JCR Pharmaceuticals (TSE:4552) and Acumen Pharmaceuticals (NASDAQ: ABOS) expanded their Alzheimer’s collaboration as Acumen exercised its exclusive option to develop, manufacture and commercialize up to two blood-brain barrier-penetrating candidates enabled by J-Brain Cargo®.
Acumen targets an IND filing in mid-2027. JCR receives an option payment and may earn up to USD 555 million in development and sales milestones plus tiered royalties. Non-clinical mouse data showed increased brain exposure while preserving AβO selectivity, and J-Brain Cargo® is clinically validated via IZCARGO™. The impact is already reflected in JCR’s fiscal 2027 earnings forecast.
Acumen Pharmaceuticals (NASDAQ: ABOS) nominated two Enhanced Brain Delivery™ (EBD™) development candidates, ACU301 and ACU401, for Alzheimer’s disease, exercising its option under a license with JCR Pharmaceuticals.
Candidates combine Acumen’s AβO-selective antibodies with JCR’s J-Brain Cargo® to enhance blood-brain barrier penetration; IND-enabling work is underway targeting mid-2027 IND submissions.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported first quarter 2026 results and Alzheimer’s pipeline updates. Cash, cash equivalents and marketable securities were $128.4 million as of Mar. 31, 2026, supported by a $35.75 million private placement, funding operations into early 2027.
R&D expenses were $16.5 million versus $25.3 million a year ago; G&A was $4.7 million versus $5.1 million. Net loss was $20.7 million, improved from $28.8 million. Topline Phase 2 ALTITUDE-AD results for sabirnetug in early Alzheimer’s are expected in late 2026, with an EBD program IND targeted for mid-2027.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026 at 8:55 a.m. PT / 11:55 a.m. ET.
The session will be webcast live and archived for 90 days under the Investors tab at the company website.
Acumen Pharmaceuticals (NASDAQ: ABOS) will report first quarter 2026 financial results on Tuesday, May 12, 2026. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Investors must register in advance to receive dial-in numbers and PIN; the webcast and an archived audio recording will be available on the company's Investors website for at least 30 days.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported 2025 results and a business update on Mar 26, 2026, highlighting clinical progress for sabirnetug and advancement of an Enhanced Brain Delivery (EBD) program.
Key items: $35.75M private placement for EBD candidates, $116.9M cash as of Dec 31, 2025 (runway into early 2027), topline ALTITUDE-AD Phase 2 results expected late 2026, and an IND target for an EBD lead candidate in mid-2027. R&D spend rose to $104.9M; net loss was $121.3M for 2025.
Acumen Pharmaceuticals (NASDAQ: ABOS) will report fourth quarter and year-end 2025 financial results on March 26, 2026 and will host a conference call and live audio webcast at 8:00 a.m. ET.
According to the company, registration is required for dial-in details, the live webcast link is provided, and an archived webcast will be available for at least 30 days in Investors on www.acumenpharm.com.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new preclinical and biomarker data at AD/PD 2026 (March 17-21) on enhanced brain delivery, NULISAseq biomarker profiling, and novel anti-amyloid beta oligomer antibodies. Key findings: TfR-targeted bispecifics increased sabirnetug brain exposure, NULISAseq measured 127 CNS proteins, and ACU234 showed ~21,000-fold oligomer selectivity.
The data support further characterization and integration with ongoing Phase 2 ALTITUDE‑AD and prior Phase 1 INTERCEPT‑AD results.